What is Pancragen 20MG

Pancragen 20MG is a synthetic tetrapeptide bioregulator of the Khavinson class studied in research for its targeted effects on pancreatic tissue and glucose metabolism. It is intended exclusively for research use.

Regarding its chemical identity, Pancragen has a molecular formula of C18H31N7O9 and a molecular weight of 489.5 g/mol. Its reported canonical sequence is Glu-Asp-Arg-Val. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Pancragen.

Product for research use.

Mechanism of action of Pancragen

Pancragen acts epigenetically on the cells of the pancreas, particularly the Islets of Langerhans. It interacts with the DNA of beta cells to stimulate the synthesis of insulin and necessary regulatory enzymes, aiming to restore the physiological function of the aging or damaged pancreas.

Pharmacokinetics and pharmacodynamics of Pancragen

Characterized by a very short plasma half-life. It acts rapidly to initiate a cascade of genetic transcription within pancreatic cells, producing metabolic regulatory effects that persist long after the peptide is degraded.

Scientific evidence on Pancragen

The available evidence on Pancragen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of Type 2 diabetes, metabolic syndrome, and age-related decline in glucose tolerance. Evidence suggests it helps normalize blood glucose levels and reduces insulin resistance by repairing the actual secretory cells rather than just forcing insulin release.

Pancragen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Pancragen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Pancragen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Pancragen

As a general guideline for laboratory handling, lyophilized peptides such as Pancragen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Pancragen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Pancragen security profile

The documented safety information in open sources for Pancragen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting pancreatic function carries theoretical risks of inducing hypoglycemia if beta cells are overstimulated. However, bioregulators are generally described in the literature as normalizers, meaning they restore homeostasis without pushing the system into an extreme pathological state.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Pancragen in a comparative context

Pancragen is the synthetic analogue of the natural pancreatic extract Suprefort. Unlike GLP-1 agonists (like Liraglutide) that rely on external receptor binding to force insulin secretion, Pancragen works at the genetic level to repair the beta cells themselves.

History and development of Pancragen

Synthesized by the St. Petersburg Institute of Bioregulation and Gerontology. It was developed to address the root cellular aging that leads to Type 2 diabetes, providing a targeted alternative to broad-spectrum metabolic drugs.